Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 693
National Institute for Health and Care Excellence (NICE)
Record ID 32018011737
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta693
Year Published:
2021
URL for published report:
https://www.nice.org.uk/guidance/ta693
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Ovarian Epithelial
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.